Novo Nordisk Triggers Price War With US Weight Loss Pill Launch

Novo Nordisk launched its Wegovy weight loss pill in the U.S. at a lower price as Eli Lilly and Nimbus Therapeutics announced a $1.3 billion partnership for oral treatments.The once-daily pill mimics the GLP-1 hormone and costs between $149 and $299 per month for self-paying patients, significantly undercutting injectable versions.Pharmaceutical analyst Matt Weston noted the pricing was lower than expected within a market projected to reach $150 billion by 2035.